IN8bio Outlines Gamma Delta T-Cell Therapy Progress in Glioblastoma and Leukemia

Got story updates? Submit your updates here. ›

IN8bio CEO William Ho detailed the company's strategy to develop cellular therapies based on gamma delta T cells, highlighting clinical progress in glioblastoma and leukemia as well as a newer internal T-cell engager program. In glioblastoma, Ho said patients treated with the company's gamma delta T cells showed a median progression-free survival of 13 months compared to 6.6 months in the control group. He also discussed preclinical data on a new CD19-targeting T-cell engager designed to activate gamma delta T cells while potentially avoiding cytokine release syndrome.

Why it matters

Glioblastoma is an aggressive and difficult-to-treat brain cancer with a poor prognosis. IN8bio's approach of leveraging gamma delta T cells to target glioblastoma tumors, including chemotherapy-resistant cells, represents a novel immunotherapy strategy. The company's new T-cell engager program also demonstrates its efforts to expand its pipeline and apply its gamma delta T-cell platform to additional oncology and autoimmune indications.

The details

IN8bio's glioblastoma protocol involves collecting a patient's blood, manufacturing personalized gamma delta T cells that are engineered to resist chemotherapy, and then infusing those cells alongside maintenance chemotherapy. In a comparison group, patients receiving the gamma delta T cells had a median progression-free survival of 13 months versus 6.6 months in the control group. The company also has an ongoing cell therapy program in leukemia patients undergoing transplantation. Additionally, IN8bio developed a new T-cell engager called INB-619 that targets CD19 and is designed to activate gamma delta T cells while potentially avoiding cytokine release syndrome.

• Patients were treated across multiple centers, including the University of Alabama at Birmingham, Cleveland Clinic, Moffitt, and Ohio State.
• As of the end of December 2025, median overall survival in the repeat-dose treated glioblastoma cohort was 17.2 months and 'still climbing.'

What they’re saying

What’s next

The company plans to seek FDA guidance on a potential registrational path forward for the glioblastoma program and expects to return to investors 'later this summer' with feedback from those discussions.